Collegium Pharmaceutical reports Q2 adjusted EPS $1.68, consensus $1.85

Reports Q2 revenue $188M, consensus $180.88M. “We continued to generate strong momentum in the second quarter, driven by sustained execution across our three strategic priorities, including record revenue from Jornay PM, maximizing our pain portfolio, and strategically deploying capital to enhance shareholder value,” said Vikram Karnani, President and Chief Executive Officer. “Following encouraging performance in the first half of the year, we anticipate a strong back-to-school season and second half of the year for Jornay PM and have raised our full-year revenue guidance accordingly. Additionally, our pain portfolio generated solid revenue growth in the quarter, reinforcing the durability of our differentiated medicines to treat chronic pain. Looking ahead, we are focused on driving additional top- and bottom-line growth as we continue to serve patients living with serious medical conditions.”